Directorate Change

Cambridge Antibody Tech Group PLC
12 September 2005

05/CAT/14

FOR IMMEDIATE RELEASE

07.00 BST, 02.00 EST Monday 12 September 2005

For Further Information Contact:
Cambridge Antibody Technology                         Weber Shandwick Square Mile (Europe)
Tel: [phone]                             Tel: [phone]
Peter Chambre, Chief Executive Officer                Kevin Smith
John Aston, Chief Financial Officer                   Yvonne Alexander
Rowena Gardner, Director of Corporate Communications  Rachel Taylor

                                                      BMC Communications/The Trout Group (USA)
                                                      Tel: [phone]
                                                      Brad Miles, ext 17 (media)
                                                      Brandon Lewis, ext.15 (investors)

CAMBRIDGE ANTIBODY TECHNOLOGY APPOINTS JOHN BROWN AS NON-EXECUTIVE DIRECTOR

Cambridge, UK - Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG) is
pleased to announce the appointment of Dr John Brown as a Non-Executive
Director, with immediate effect.

John has extensive experience of the biopharmaceutical industry having held a
number of positions within the sector. He was most recently Chief Executive
Officer at Acambis plc where he developed and implemented a strategy to develop
new products, exploit platform technologies and achieve profitability. Prior to
joining Acambis as Finance Director, John worked as Head of Research at
Sutherland & Partners (Edinburgh) Ltd and as a Pharmaceutical Analyst at Bell
Lawrie White. Before this, he consulted widely for pharmaceutical and
biotechnology companies at PA Consulting Group. Following his post-doctoral work
with the MRC, John joined Glaxo Group Research, where he led a team developing
small molecule therapeutics and completed his MBA.

John currently Chairs the Governing Council of the Roslin Institute in Edinburgh
and is Chairman of Scottish Biomedical and BIA Scotland. In addition, he
currently holds a number of non-executive directorships within the biotechnology
industry. These include positions at Protherics plc, Vectura plc and OnyVax Ltd.
He also sits on the Advisory Board of the Life Sciences ITI in Scotland, and is
a member of the DTI Technology Strategy Board and the DTI Biotechnology
Leadership Council. Previous directorships include Acambis plc and Roslin
Biomed.

Paul Nicholson, CATs Chairman, commented: We are delighted to welcome John Brown
as a Non-Executive Director of CAT. He has widespread commercial, financial and
scientific experience within the biotechnology industry and we have no doubt
that he will make a significant contribution to the Board and CATs development.
John will also join the Audit Committee and the Remuneration Committee.

- ENDS -

Appendix

CAT hereby confirms that no information is disclosable in relation to the
appointment of John Brown pursuant to the requirements of Listing Rule 9.6.13
paragraphs (1)-(6).

Notes to Editors:

John Brown - Biography and Details
Education:

University of Edinburgh (BSc Hons Pharmacology: PhD Neuropharmacology)

Middlesex Business School (MBA)

Career details:

1981-1986 Glaxo Group Research: Research Pharmacologist

1986-1991 PA Consulting Group: Consultant, Senior Consultant, Principal

1991-1993 Bell Lawrie White: Pharmaceutical Analyst

1993-1995 Sutherland & Partners: Head of Research

1995-2004 Acambis plc: Finance Director: Chief Executive Officer

Nationality: British

Marital Status: Married

Age: 50

Cambridge Antibody Technology (CAT):

Business:

CAT is a biopharmaceutical company, aiming to bring improvements to seriously
ill patients lives and thereby create outstanding returns for shareholders. CAT
seeks to develop products independently and in collaboration with partners,
using its capabilities and technologies in the discovery and development of new
and innovative antibody medicines in selected therapeutic areas. CAT also seeks
to licence its technologies to enable others to develop new medicines.

CAT has strong financial foundations which arise from its balance sheet strength
and the revenue stream from HUMIRA(R) royalties. The diversified pipeline of
licensed antibody product candidates offers good prospects for growth in the
medium term and significant longer term opportunities arise from CATs
proprietary development and alliances, especially with Genzyme and AstraZeneca.

Products:

HUMIRA, licensed to Abbott, is the first CAT-derived antibody to be approved for
marketing. It was isolated and optimised in collaboration with Abbott and has
been approved for marketing as a treatment for rheumatoid arthritis (RA) in 57
countries, and for psoriatic arthritis and early RA in some European countries.

There are six further CAT-derived antibodies licensed to partners at various
stages of clinical development, including ABT-874 (Abbott), LymphoStat-B,
HGS-ETR1, HGS-ETR2 (all Human Genome Sciences (HGSI)) and MYO-029 (Wyeth). CAT
has also licensed its proprietary technologies and patents to several companies.
CATs licensees include Abbott, Amgen, Chugai, Dyax, Genzyme, HGSI, Merck & Co,
Micromet, Pfizer and Wyeth, and three antibody drug candidates are in clinical
development at patent licensees.

There is one proprietary CAT human therapeutic antibody product candidates in
clinical development, CAT-354, and one in pre-clinical development with Genzyme,
GC-1008.

Collaborations:

CAT has a broad collaboration with Genzyme for the development and
commercialisation of antibodies directed against TGF beta, a family of proteins
associated with fibrosis and scarring, and with potential application in the
treatment of some cancers.

CAT has a major strategic alliance with AstraZeneca to discover and develop
human antibody therapeutics, principally in inflammatory disorders. This
provides CAT with the opportunity to build a substantial pipeline of antibody
therapeutics with a significant pharmaceutical partner.

CAT has a co-development collaboration with Amrad against GM-CSF Receptor, a
potential drug target in the development of RA.

Science:

CAT has an advanced proprietary technology for rapidly isolating human
monoclonal antibodies using Phage Display and Ribosome Display systems. CAT has
extensive phage antibody libraries, currently incorporating more than 100
billion distinct antibodies, which form the basis for the Companys strategy to
develop a portfolio of antibody-based drugs.

Business Background:

Based near Cambridge, UK, CAT currently employs around 290 people.

CAT is listed on the London Stock Exchange (CAT) and on NASDAQ (CATG).

More information can be found at www.cambridgeantibody.com

Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995: This press release contains statements about Cambridge Antibody
Technology Group plc ("CAT") that are forward looking statements. All statements
other than statements of historical facts included in this press release may be
forward looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934. These forward looking statements are based on numerous
assumptions regarding the companys present

and future business strategies and the environment in which the company will
operate in the future. Certain factors that could cause the companys actual
results, performance or achievements to differ materially from those in the
forward looking statements include: market conditions, CATs ability to enter
into and maintain collaborative arrangements, success of product candidates in
clinical trials, regulatory developments and competition. We caution investors
not to place undue reliance on the forward looking statements contained in this
press release. These statements speak only as of the date of this press release,
and we undertake no obligation to update or revise the statements.




                      This information is provided by RNS
            The company news service from the London Stock Exchange